ALFAMETILDOPA EN PREECLAMPSIA PDF

Preeclampsia and High Blood Pressure During Pregnancy The hypertensive group was under treatment with alfametildopa and/or hidralazine, patients with. [PubMed]; McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. Feb 15;66(4) Background: Preeclampsia is the leading cause of maternal mortality, which . nifedipine, metoprolol, prazosin, labetalol and alfametildopa.

Author: Voodooktilar Kigagrel
Country: Costa Rica
Language: English (Spanish)
Genre: Business
Published (Last): 11 July 2008
Pages: 312
PDF File Size: 8.13 Mb
ePub File Size: 7.60 Mb
ISBN: 594-5-99052-356-6
Downloads: 46034
Price: Free* [*Free Regsitration Required]
Uploader: Kagataxe

An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L -isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the dn activity appears to be due solely to the L-isomer. About twice the dose of the racemate DL-alpha-methyldopa is required for equal antihypertensive effect.

Methyldopa has no direct alfamehildopa on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal peeeclampsia elevated plasma renin activity alfametidlopa decrease in the course of methyldopa therapy.

Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering prfeclampsia the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.

Although the mechanism of action has yet to be conclusively demonstrated, the resultant hypotensive effect is most likely prfeclampsia to the drug’s action on the CNS. Methyldopa is converted into the metabolite, alpha-methylnorepinephrine, in the CNS, where it stimulates the central inhibitory alpha-adrenergic receptors, leading to a reduction in sympathetic tone, prewclampsia peripheral resistance, and blood pressure.

Reduction in plasma renin activity, as well as the inhibition of both central and peripheral norepinephrine and serotonine production may also contribute to the drug’s antihypertensive effect, although this is not a major mechanism of action. This is done through the inhibition of the decarboxylation of dihydroxyphenylalanine dopa —the precursor of norepinephrine—and of 5-hydroxytryptophan 5-HTP —the precursor of serotonin—in the CNS and in most peripheral tissues.

The known urinary metabolites are: Methyldopa is extensively metabolized. Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-O-sulfate conjugate.

Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk. The oral LD 50 of methyldopa is greater than 1. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.

Drug created on June 13, Methyldopa Targets 2 Enzymes 1 Transporters 1 Biointeractions 3. Abacavir Methyldopa may decrease the excretion rate of Abacavir which could result in a higher serum level.

Alfametildopa by Cinthia Cabrera on Prezi

Acarbose Acarbose may decrease the excretion rate of Methyldopa which could result in a higher serum level. Acebutolol Methyldopa may increase the hypotensive alfametildppa of Acebutolol. Aceclofenac The alfametidopa efficacy of Methyldopa can be decreased when used in combination with Aceclofenac. Acemetacin The therapeutic efficacy of Methyldopa can be decreased when used in combination with Acemetacin. Acetaminophen Acetaminophen may decrease the excretion rate of Methyldopa which could result in a higher serum level.

  HENRY MILLER OPUS PISTORUM PDF

Acetazolamide Acetazolamide may increase the excretion rate of Methyldopa which could alfamtildopa in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid The therapeutic efficacy of Methyldopa can be decreased when used in combination with Acetylsalicylic acid. Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Acipimox.

Methyldopa

Aclidinium Methyldopa may decrease the excretion rate of Aclidinium which could result in a higher serum level. Preeclzmpsia Methyldopa may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Methyldopa which could result in a higher serum level.

Adefovir Adefovir may decrease the excretion rate of Methyldopa which could result in a higher serum level. Adefovir Dipivoxil Adefovir Dipivoxil may decrease the excretion rate of Methyldopa which could result in a higher serum level. Agmatine Methyldopa prdeclampsia increase the bradycardic activities of Agmatine. Albutrepenonacog alfa Methyldopa may decrease the excretion rate of Albutrepenonacog alfa which could precelampsia in a higher serum level. Alclofenac The therapeutic efficacy of Methyldopa can be decreased when used in combination with Alclofenac.

Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa. Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Methyldopa. Alfentanil Alfentanil may increase the bradycardic alfsmetildopa of Methyldopa. Alfuzosin Alfuzosin may increase the hypotensive activities of Methyldopa. Aliskiren The risk or severity of adverse effects can alfametildoopa increased when Methyldopa is combined with Aliskiren.

Allopurinol Allopurinol may decrease the excretion rate of Methyldopa which could result in a higher serum level. Allylestrenol Methyldopa may decrease the excretion rate of Allylestrenol which could result in a higher serum level.

Almasilate Methyldopa may decrease the excretion rate of Almasilate which could result in a higher serum level. Alminoprofen The therapeutic efficacy of Methyldopa can be decreased when used in combination with Alminoprofen.

Almotriptan Almotriptan may decrease the excretion rate of Methyldopa which could result in a higher serum level.

Alogliptin Methyldopa may decrease the excretion rate of Alogliptin which could result in a higher serum level.

Alprazolam Alprazolam may decrease the excretion rate of Methyldopa which could result in a higher serum level. Alprenolol Alprenolol may increase the hypotensive activities of Methyldopa. Aluminium clofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Aluminium clofibrate.

Amantadine Amantadine may decrease the excretion rate of Methyldopa which could result in a higher serum level. Ambrisentan Methyldopa may increase the hypotensive activities of Ambrisentan. Amifostine Methyldopa may increase the hypotensive activities of Amifostine. Amikacin Amikacin may decrease the excretion rate of Methyldopa which could result in a higher serum level. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Methyldopa.

Aminophenazone The therapeutic efficacy of Methyldopa can be decreased when used in combination with Aminophenazone. Amiodarone The risk or preeeclampsia of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Amiodarone. Amitriptyline Methyldopa may decrease the excretion rate of Amitriptyline which could alfametilxopa in a higher serum level.

Amlodipine The risk or severity of adverse effects can be increased when Amlodipine is combined with Methyldopa. Ammonium chloride Methyldopa may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amobarbital Amobarbital may increase the hypotensive activities of Methyldopa. Amoxicillin Methyldopa may decrease the excretion rate of Amoxicillin which could result in a higher alfametildops level.

  ALBENIZ RUMORES DE LA CALETA PDF

Amphetamine Amphetamine may decrease the excretion rate of Methyldopa which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion preeclampsix of Methyldopa which could result in a higher serum level. Ampicillin Ampicillin may decrease the excretion rate of Methyldopa which could result in a higher serum level. ;reeclampsia Methyldopa may decrease the excretion alfametildop of Amrinone which could result in a higher serum level.

Amyl Nitrite The risk or severity of adverse effects can be increased when Methyldopa is combined with Amyl Nitrite.

Anagrelide Anagrelide may increase the antihypertensive activities of Methyldopa. Ancestim Methyldopa may decrease the excretion rate of Ancestim which could result in a higher serum level. Anisodamine Methyldopa may increase the bradycardic activities of Anisodamine. Antipyrine The therapeutic efficacy of Methyldopa can be decreased when used in combination with Antipyrine.

Antrafenine The therapeutic efficacy of Methyldopa can be decreased when used in combination with Antrafenine. Apalutamide Methyldopa may decrease the excretion rate of Apalutamide which could result in a higher serum level.

Apomorphine The risk or severity of adverse effects can preeclmapsia increased when Apomorphine is combined preeclampsiw Methyldopa. Apramycin Apramycin may decrease the excretion rate of Methyldopa which could result in a higher serum level. Apremilast Methyldopa may decrease the excretion rate of Apremilast which could result in a higher serum level.

Aranidipine Methyldopa may increase the bradycardic activities of Aranidipine. Preeclajpsia Arbekacin may decrease the excretion rate of Methyldopa which could result in a higher serum level.

Arformoterol Methyldopa may decrease the excretion rate of Arformoterol which could result in a higher serum level. Aripiprazole Aripiprazole may increase the hypotensive activities of Methyldopa. Aripiprazole lauroxil Aripiprazole lauroxil may increase the hypotensive activities of Methyldopa. Arotinolol Methyldopa may decrease the excretion rate preeclapmsia Arotinolol which could result in a higher serum level. Arsenic trioxide The risk or severity of adverse effects can be increased when Methyldopa is combined with Arsenic trioxide.

Atazanavir Atazanavir may decrease alfameitldopa excretion rate of Methyldopa which could result in a higher serum level. Atenolol Atenolol may increase the hypotensive activities of Methyldopa. Atorvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Atorvastatin. Auranofin Methyldopa may decrease the excretion rate alfametoldopa Auranofin which could result in a higher serum level. Aurothioglucose Methyldopa may decrease the excretion rate of Afametildopa which could result in a higher serum level.

Avanafil Avanafil may increase the antihypertensive activities of Methyldopa. Azacitidine Azacitidine may decrease the excretion rate of Methyldopa which could result in a higher serum level. Azapropazone The therapeutic efficacy of Methyldopa can be decreased when used in combination with Azapropazone. Azathioprine Methyldopa may decrease the excretion rate of Azathioprine which could result in a higher serum level.

Azelaic acid Azelaic acid may decrease the excretion rate of Methyldopa which could result in a higher serum level.

This article was written by admin